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Evaluating Diuretics in Normal Care
(EVIDENCE): protocol of a cluster
randomised controlled equivalence trial of
prescribing policy to compare the
effectiveness of thiazide-type diuretics in
hypertension
Amy Rogers* , Angela Flynn, Isla S. Mackenzie, Lewis McConnachie, Rebecca Barr, Robert W. V. Flynn,
Steve Morant, Thomas M. MacDonald and Alexander Doney
Abstract
Introduction: Healthcare systems must use treatments that are effective and safe. Regulators licensed many
currently used older medications before introducing the stringent evidential requirements imposed on modern
treatments. Also, there has been little encouragement to carry out within-class, head-to-head comparisons of
licensed medicines. For commonly prescribed drugs, even small differences in effectiveness or safety could have
significant public health implications. However, conventional clinical trials that randomise individual subjects are
costly and unwieldy. Such trials are also often criticised as having low external validity. We describe an approach to
rapidly generate externally valid evidence of comparative safety and effectiveness using the example of two widely
used diuretics for the management of hypertension.
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Methods and analysis: The EVIDENCE (Evaluating Diuretics in Normal Care) study has a prospective, cluster-
randomised, open-label, blinded end-point design. By randomising prescribing policy in primary care practices, the
study compares the safety and effectiveness of commonly used diuretics in treating hypertension. Participating
practices are randomised 1:1 to a policy of prescribing either indapamide or bendroflumethiazide when clinically
indicated. Suitable patients who are not already taking the policy diuretic are switched accordingly. All patients
taking the study medications are written to explaining the rationale for changing the prescribing policy and
notifying them they can opt-out of any switch. The prescribing policies’ effectiveness and safety will be compared
using rates of major adverse cardiovascular events (hospitalisation with myocardial infarction, heart failure or stroke
or cardiovascular death), routinely collected in national healthcare administrative datasets. The study will seek to
recruit 250 practices to provide a study population of approximately 50,000 individuals with a mean follow-up time
of two years. A primary intention-to-treat time-to-event analysis will be used to estimate the relative effect of the
two policies.
Ethics and dissemination: EVIDENCE has been approved by the East of Scotland Research Ethics Service (17/ES/
0016, current approved protocol version 5, 26 August 2021). The results will be disseminated widely in peer
reviewed journals, guideline committees, National Health Service (NHS) organisations and patient groups.
Trial registration: ISRCTN46635087. Registered on 11 August 2017 (pre-recruitment).
Keywords: Medical record linkage, Comparative effectiveness research, Drug prescriptions, Primary health care,
Hypertension
Background
Formal comparisons of the effectiveness and safety of
medicines with similar modes of action and indication
are rare [1]. As the number of available medicines in-
creases, high-quality evidence of comparative effective-
ness becomes increasingly essential. This problem was
the subject of two recent Lancet reviews and accom-
panying commentary that promoted comparative effect-
iveness research for public health [2–4].
Randomised placebo-controlled trials (RCTs), often
considered the gold standard for generating healthcare
evidence, can be cumbersome, expensive and time-
consuming [5]. Such trials often have low external valid-
ity because trial participants are likely to differ from pa-
tients encountered in usual healthcare practice [6]. As it
is conventionally conducted, the randomised controlled
trial is not a suitable tool for generating comparative ef-
fectiveness evidence at the required scale and speed. A
more efficient method that can generate evidence within
acceptable boundaries of precision and within reasonable
time frames and resources is needed.
The potential for using routinely collected data to gen-
erate knowledge within a learning healthcare framework
is increasingly recognised [7]. Whilst such data can be
used to produce evidence quickly and efficiently, non-
interventional research is subject to biases that limit its
usefulness for clinical decision making [8]. The result is,
despite significant advances in causal inference tech-
niques [9, 10], purely observational research often fails
to influence policy and behaviour [8]. Researchers can
enhance the value of these large datasets by combining
them with the essential features of randomised trials and
healthcare system-specific processes.
We describe a study design that uses routinely col-
lected healthcare data in combination with cluster ran-
domisation to generate high-quality evidence of
comparative effectiveness of prescribing policy efficiently
and rapidly. Using the example of thiazide-type diuretic
medications, widely used for managing hypertension, the
EVIDENCE (EValuatIng DiurEtics in Normal CarE)
study will compare policies for prescribing indapamide
or bendroflumethiazide. Previous work by our group has
demonstrated good public support for this type of re-
search [11]. Whilst we have developed the EVIDENCE
protocol using the exemplar of diuretic medicines, the
infrastructure and methodology will be applicable to the
wide range of situations where comparative safety and
effectiveness evidence is lacking for treatments com-
monly used in the NHS.
Rationale for EVIDENCE
Cardiovascular diseases are the leading cause of death
worldwide with high blood pressure being the most
common preventable cause, responsible for 54% of
strokes and 47% of ischaemic heart disease [12]. Given
the high prevalence of hypertension, affecting around
12.5 million people in England in 2015 [13], even slight
differences in the effectiveness or safety between widely
prescribed blood pressure-lowering medications would
imply many thousands of potentially avoidable events.
Thiazide and thiazide-like diuretics are a cornerstone
of hypertension treatment. The scant evidence for
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clinically relevant differences between the thiazide and
thiazide-like diuretics has been interpreted variably by
blood pressure management guidelines internationally
[14]. In 2011, the UK NICE guidelines for managing
hypertension [15] stated that “a thiazide-like diuretic,
chlortalidone or indapamide, should be chosen in prefer-
ence to a conventional thiazide diuretic such as bendro-
flumethiazide or hydrochlorothiazide”. The guidelines
development group (GDG) conceded that “there were
no direct comparisons between the different diuretics
with regard to clinical outcomes” and that “the GDG
found it difficult to reach firm conclusions regarding the
comparative efficacy of different thiazide-type diuretics
with regard to blood pressure-lowering” [15]. Before this
guidance, UK diuretic use for hypertension was almost
entirely restricted to bendroflumethiazide [16, 17]. The
2011 guideline was therefore suggesting a significant
change to the prevalent prescribing of these drugs. The
2019 guideline update, NG136, still recommends a
thiazide-like diuretic in preference to a conventional
thiazide [18].
The interpretation of the evidence by the GDG has
been disputed [19]. A recent meta-analysis from our
group has further demonstrated the lack of evidence in
this area [20]. Despite NICE guidance, bendroflumethia-
zide remains the dominant diuretic prescribed in the UK
to treat hypertension [16]. The hypertension community
remains in equipoise about diuretic choice, and many
local prescribing policies did not take up the NICE rec-
ommendation. This situation is likely to have also been
influenced by chlortalidone not being readily available in
the UK and indapamide being significantly more expen-
sive than bendroflumethiazide [21].
To conduct a conventional individually randomised
clinical trial comparing the effects of bendroflumethia-
zide and indapamide on cardiovascular outcomes would
be very challenging; such a trial would likely require the
recruitment of over 50,000 individual patients, making it
one of the largest hypertension trials ever. Furthermore,
as both drugs are now off-patent, securing sufficient
funding to achieve this level of recruitment for this com-
parison and many others within current health research
funding structures would be a formidable task. There-
fore, we propose the EVIDENCE trial design as a prag-
matic solution to the problem of how to conduct
comparative effectiveness research within existing
constraints.
Objectives
The primary objective of EVIDENCE is to estimate the
relative effectiveness of two prescribing policies for the
management of hypertension in terms of both safety and
efficacy. If study results suggest that there is no clinically
relevant difference [22], this will justify individual
prescribers and healthcare providers continuing to de-
cide which drug to offer based on other relevant factors
such as availability and price.
Our secondary objective is to evaluate the feasibility of
the EVIDENCE method for conducting clinical effective-
ness research in the NHS. We intend that this method-




EVIDENCE is a cluster-randomised, prospective,
parallel-group, blinded outcome study comparing car-
diovascular event rates in patients in general practices
being prescribed either bendroflumethiazide or indapa-
mide to manage hypertension.
The cluster randomised approach has been chosen to
increase the feasibility of performing comparative effect-
iveness research at scale in the NHS; the cost of con-
ducting multiple comparisons of commonly used
medicines using individual patient recruitment and ran-
domisation would be prohibitive. However, this feasibil-
ity advantage must be balanced against a need for
careful statistical planning [23, 24].
There is, nonetheless, an important advantage of clus-
ter randomisation without individual opt-in consent over
more traditional approaches: using an opt-out of inter-
vention approach is likely to result in a study cohort far
more representative of the intended patient population
[25, 26].
NHS general medical practices using electronic med-
ical records will be invited to take part in the study. The
study will recruit practices from a broad range of NHS
trusts, including remote and rural practices that are
often excluded from traditional trial participation. The
study is designed to be minimally disruptive to practice
workflow and uses routine prescribing activities. Recruit-
ment of general practices and randomisation of prescrib-
ing policy at the practice level allows the rapid accrual of
a large observational study population whilst incorporat-
ing the statistical benefits of randomisation. Routinely
collected national datasets of hospitalisations and deaths
will be used to compare cardiovascular event rates be-
tween individuals being treated under each of the two
policies. National dispensed prescribing information will
be used to facilitate the definition of analysis cohorts.
General practice data will be used to gather evidence on
potentially important adverse effects such as electrolyte
and metabolic disturbances. The study will take place in
Scotland where national datasets are well established, al-
though we anticipate that extension to other regions of
the UK would be feasible. Figure 1 shows the EVI-
DENCE study flow diagram.
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Identification of the study population
A search will be performed in each recruited practice
using a bespoke EHR-specific tool to identify patients
who may be subject to a medication switch after policy
randomisation based on the following criteria.
Inclusion criteria
 Documented diagnosis of hypertension (on practice
hypertension register)
 Currently receiving repeat prescriptions for
bendroflumethiazide or indapamide
 Aged over 18
Exclusion criteria
 Documented history of an adverse drug reaction to
either medication
 History of having been prescribed both thiazide-like
diuretics at different times, indicating a potential
clinical reason for not being able to take one or
other
 Other cogent clinical or other indication for not
switching medication (see below)
A draft list of potential patients identified in each
practice will be provided to a relevant member of the
primary care team (a practice GP or delegate) for ap-
proval. Approval will include the redaction of any indi-
viduals considered not suitable for the drug switch,
based on local knowledge. The approved list will be used
for the study and represents the study population for the
practice.
Cluster randomisation
The randomisation unit in this study is the practice (the
cluster); patients are not individually recruited. Follow-
ing identification and approval of the practice study
population, the practice will be randomised using an on-
line study portal. Randomisation will be 1:1, block bal-
anced by practice list size, using a computerised
randomisation algorithm. Block sizes are randomly allo-
cated to prevent staff implementing the trial from guess-
ing the next allocation. The prescribing policies will be
GP Practices recruited
GP Practices randomised (n~250)
Practice allocated to
bendroflumethiazide-first policy






Eligible patients identified and approved
Letter sent to patients (information and
switch opt-out instructions)
Switching of repeat prescribing (as
required) to bendroflumethiazide
Eligible patients identified and approved
Letter sent to patients (information and
switch opt-out instructions)





(within min. 28 days)







Fig. 1 EVIDENCE study flow diagram
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applied at a practice level, and individual prescribers will
remain free to prescribe as clinically appropriate.
Intervention
Policy medications
 Bendroflumethiazide is licensed for the treatment of
hypertension and oedema, although by far the most
common indication is hypertension. The typical
dose for hypertension is 2.5 mg once daily. A small
minority of patients are prescribed 5 mg or 1.25 mg
daily.
 Indapamide is licensed to treat hypertension only at
2.5 mg/day, although tablets are scored and 1.25 mg
can be taken. It is also available as a more expensive
slow-release preparation at a dose of 1.5 mg. The
2.5 mg standard release formulation will be used in
this study.
Policy implementation
Informing patients about the study
Immediately following randomisation of a practice, all
patients in the study population will be written to
informing them that their practice is taking part in the
EVIDENCE study. The letter will be printed on practice-
specific headed paper and will briefly explain why the
study is being conducted. It will also advise that the
patient's repeat prescriptions for thiazide-type medica-
tion may be switched in line with the newly assigned
practice prescribing policy. The letter directs patients
who may have any questions, concerns, or objections to
visit a study-specific website (www.memoresearch.com/
evidence) or directly contact the study team. The study
team will provide further information and, if the patient
confirms that they would prefer to opt-out of any switch
and remain on their current medication, the study team
will not action the switch for that individual.
Repeat prescription switching
Patients whose current medication prescription is con-
cordant with the randomly assigned policy will remain
on their existing strength and dosage of thiazide-type di-
uretic. Where a patient is not being prescribed for in
concordance with the randomly assigned policy, future
repeat prescriptions will be altered as follows:
1. Bendroflumethiazide 2.5 mg or 5 mg will be
changed to indapamide (standard release) 2.5 mg.
2. Indapamide 2.5 mg will be changed to
bendroflumethiazide 2.5 mg.
3. Indapamide 1.5 mg (modified release) will be
changed to bendroflumethiazide 2.5 mg.
Practices assigned to indapamide will also be offered
the choice of having any existing indapamide 1.5 mg
modified release prescriptions switched to the more
cost-effective 2.5 mg version, in keeping with the NICE
guidelines.
The study pharmacist/technician will facilitate any
prescription changes using established practice prescrib-
ing management procedures. All procedures for imple-
menting switches are specified in a study Operations
Manual. After the initial switching phase, all patients
who newly require a thiazide-type diuretic for hyperten-
sion will be subject to the randomly assigned policy.
Where possible, integrated electronic practice formular-
ies will be updated to remind prescribers of the policy
when issuing new prescriptions for thiazide/thiazide-like
diuretics.
Patient and public involvement
During the study pilot, feedback on study materials and
methods was sought from patients and healthcare staff
who contacted the study team. This feedback was incor-
porated into improved patient letters and switching
methods. Our research unit’s public involvement group
have discussed the research proposal and design, provid-
ing essential guidance on preferred patient communica-
tion methods. A study-specific patient involvement
group will be formed to advise the study management
group on ongoing patient communications and
dissemination.
Outcomes
Primary and secondary outcomes will be determined at
an individual level and identified by individual-level rec-
ord linkage of practice study populations to de-identified
NHS datasets.
Primary outcome
MACE (major adverse cardiac event) is a widely ac-
cepted composite end-point employed for hypertension
trials [27]. For this study, we define MACE as a hospital-
isation for myocardial infarction, coronary revascularisa-
tion, stroke or heart failure, or vascular death.
Secondary outcomes
 Individual components of the primary outcome
 All-cause mortality
 Metabolic complications (hypokalaemia and
hyponatraemia)
 New diabetes mellitus diagnoses
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Tertiary outcomes
We will evaluate the method in terms of practice work-
load and acceptability, subsequent prescribing patterns,
and treatment escalation.
NHS data sets
These data will be provided by the electronic Data Re-
search and Innovation Service (eDRIS), a part of Public
Health Scotland. Permission to do this has been ob-
tained from the Public Benefit and Privacy Panel for
Health and Social Care (HSC-PBPP). If practices in other
parts of the UK are recruited, this information will be
obtained through the relevant national agencies.
Dispensed prescribing data for participating practices
will be linked to Scottish hospitalisation (SMR01) and
National Records of Scotland (NRS) death registration
datasets. General practice data will complement these
national datasets and allow more accurate ascertainment
of secondary outcomes.
All analyses will use anonymised data within a secure
research environment, accredited under the NHS Digital
- Data Security and Protection Toolkit and the eDRIS
National Safe Haven.
Clinical adjudication of cardiovascular events
The use of routinely collected NHS data for determining
cardiovascular end-points for clinical trials is practical
and cost-effective. It has been used extensively for large
pragmatic trials with careful adjudication of all end-
points by a specialised clinical committee [28–31]. How-
ever, as administrative data improves, it seems increas-
ingly feasible to use the data without formal adjudication
[32, 33]. We intend to adjudicate a proportion of out-
come events identified from administrative data to esti-
mate the sensitivity and specificity of administrative
diagnostic coding in the study population. This process
will require de-anonymisation of the individuals experi-
encing these events for clinical record retrieval. We have
established and standardised procedures to do this based
on previous and ongoing trials [34].
Analyses and statistical methods
Using an intention-to-treat approach, the primary study
analysis will use a baseline covariate-adjusted time-to-
event individual patient-level analysis (proportional haz-
ards model, if appropriate) to estimate the relative effect-
iveness of the two prescribing policies in preventing the
primary outcome. We will adjust for a range of pre-
specified covariates, including age, sex, co-morbidities
and the Scottish Index of Multiple Deprivation [35]. This
primary analysis will be of most use to policymakers in
determining whether, as NICE guidance suggests, pre-
scribers should be directed to favour one drug over the
other.
We will perform a similar analysis using an as-treated
approach to estimate the relative effectiveness of the two
medications in preventing the primary outcome. This
analysis will address the cited lack of direct comparative
effectiveness evidence for these two drugs.
Randomisation and the large sample size (i.e. a large
number of practices randomised) should reduce bias
from an imbalance of baseline covariates. However, a
range of sensitivity analyses will be performed to explore
residual biases, including selection bias and differential
adherence.
A detailed statistical analysis plan will be prepared and
published.
Sample size
EVIDENCE is a cluster randomised study; statistical
power, therefore, depends on the number of practices,
the mean number of patients in each practice and the
event rate and their variability between practices. We
used data obtained from the Clinical Practice Research
Datalink for the Bendroflumethiazide versus Indapamide
for Primary Hypertension: Observational (BISON) study
to estimate these variables [36]. First, we identified pa-
tients similar to the expected EVIDENCE study popula-
tion and found an average of 200 individuals per
practice, but with substantial variation in numbers be-
tween practices (standard deviation 140). We then de-
fined an arbitrary index date and calculated the
incidence of the EVIDENCE composite endpoint follow-
ing that date. The overall event rate was 0.0305 per
patient-year (0.0265 in patients with no previous out-
come event and about six times higher in the 7% of
follow-up time for patients with an earlier event). Finally,
we estimated the between-practice standard deviation to
be 0.0047.
Using these parameters, we ran simulations using ran-
dom samples of 250 practices (sample size 50,000) with
a mean follow-up time of 2 years and clinically plausible
relative risks between treatments of 1.1 to 1.2. We also
allowed the possibility that the BISON study overesti-
mated the event rate by a factor of 2 or 3. We fitted
mixed-effects models, in which variation between prac-
tices was treated as a random effect, and prior history
was treated as a patient-level fixed effect, to estimate the
confidence interval for the relative risk between treat-
ments. Finally, we conducted a 2-sided test of the super-
iority of one treatment over the other. Assuming event
rates are close to those found in the BISON study, a
study size of 50,000 individuals (250 practices) will have
80% power to detect a relative risk of about 1.12 be-
tween treatments. If the event rate is 2 or 3 times lower,
this study will have 80% power to detect relative risks of
1.16 and 1.19, respectively.
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Study conduct
Study management group
An executive study committee will be constituted to
guide the day to day running of the study. This group
will consist of three of the principal investigators. An ex-
ternal advisor will be invited to join the study executive.
Independent data monitoring committee
An independent data monitoring committee will be con-
vened. The committee will comprise experienced phar-
macoepidemiologists and clinicians with hypertension
experience, as well as a trial statistician. The committee
will receive unblinded data and will be expected to rec-
ommend changes to the conduct of the study, including
early stopping of recruitment, based on their assessment
of the relative risk/benefit of the study intervention. The
committee will meet at least annually and will report to
the study management group.
Study management
A study pharmacist and clinical research fellow will
oversee the study and will be accountable to the Chief
Investigator (CI). The study pharmacist and clinical re-
search fellow will be responsible for checking practice
derived data for completeness, plausibility and
consistency. However, this remains the overall responsi-
bility of the CI. Any queries will be resolved by the CI or
delegated member of the study team.
Quality assurance
Since this study intervention is a randomised policy de-
sign, and there are no investigational medicinal prod-
ucts, no formal study monitoring is proposed. Principal
investigators and institutions involved in the study will
permit quality assurance audits or REC review as re-
quired by the sponsor. In the event of such a review, the
investigators agree to allow the sponsor, representatives
of the sponsor or regulatory authorities access to all re-
cords held by MEMO Research. Where such access is
required, persons accessing study data will need to meet
the standard conditions permitting such access. It should
be noted that all person-specific study data will remain
in GP practices and the eDRIS safe haven.
The EVIDENCE study will be undertaken by MEMO
Research (www.memoresearch.com) and is sponsored by
the University of Dundee and NHS Tayside (Sponsor
R&D Number 2016CV12). The study has been approved
by the East of Scotland Research Ethics Service (REC
Number 17/ES/0016) and registered with ISRCTN
(46635087). The Medicines and Health products Regula-
tory Agency has deemed that the EVIDENCE study is
not a Clinical Trial of an Investigational Medicinal Prod-
uct because it is an evaluation of prescribing policies for
licensed medications.
Protocol amendments
Any changes to the study protocol, except those neces-
sary to remove an apparent, immediate hazard, will be
reviewed and approved by the CI and sponsor. Amend-
ments to the protocol will be submitted in writing for
approval by the appropriate regulatory and ethical au-
thorities before implementation.
Dissemination
The results of this study will be disseminated through
national and international conferences and papers.
Authorship criteria will be based on recommendations
of the International Committee of Medical Journal Edi-
tors. The results will also be shared with guideline com-
mittees, NHS organisations and patient groups.
Discussion
EVIDENCE uses a new pragmatic trial method, combin-
ing essential elements of randomised clinical trials and
observational analysis of routine clinical data collection
and making use of routine NHS prescribing manage-
ment activities. Cluster randomisation allows very large
numbers of patients to be rapidly included in a study, fa-
cilitating an adequately powered study of short duration.
This method provides a research infrastructure for rapid
and highly efficient generation of evidence of compara-
tive effectiveness of medications in situations where clin-
ical equipoise exists.
In addition to the sample size considerations described
above, cluster randomised trials are potentially vulner-
able to significant imbalance in baseline covariates, lead-
ing to reduced statistical precision [24]. Although we
have used block randomisation stratified by practice size
to mitigate some cluster-level covariate imbalance, this
may not be sufficient to account entirely for imbalance
in cluster and individual patient-level baseline covariates,
despite the relatively large number of clusters. For this
reason, we plan a covariate-adjusted statistical analysis.
Alternative methods of achieving balance at baseline,
such as minimisation or covariate-constrained random-
isation, should be considered for future trials using this
design [24]. However, such approaches may be limited
by lack of access to suitable data to calculate baseline co-
variate means and would increase the complexity of the
study implementation in individual practices.
The primary intention-to-treat analysis will be suscep-
tible to bias due to differential adherence. Although pa-
tients will not pay for either medication (all
prescriptions are free within the NHS in Scotland), we
may still expect differences in medication adherence be-
tween arms. For example, a patient experiencing minor
symptoms may be more likely to attribute them to a
new-to-them medication and discontinue or take the
medication only intermittently, compared to a similar
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patient whose prescription has been unchanged. There-
fore, the planned secondary as-treated analysis using dis-
pensed prescribing data will be essential to interpreting
the results.
Whilst we have tested the feasibility and acceptability
of these methods, scaling the study nationally may be
challenging. A successful national study will rely on
close collaboration between the research team, partici-
pating practices, health boards and national data pro-
viders. This multi-disciplinary approach to health
services research will be vital in achieving a genuinely
learning healthcare system.
Trial status
This manuscript describes approved protocol version 5,
26 August 2021. Recruitment to the pilot study began in
October 2017, and full study recruitment is expected to
continue until February 2024 (approximate).
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